Literature DB >> 34131224

Long-term prognosis of vascular access in hemodialysis patients with systemic lupus erythematosus: a retrospective cohort study.

Yung-Tai Chen1,2,3,4, Chih-Ching Lin5,6,7, Fan-Yu Chen1,2,8, Chun-Fan Chen1,2,9, Ann Charis Tan8, Chia-Hao Chan8, Fu-An Chen1,2,9, Wen-Sheng Liu1,2,10,11,12,13,3, Tz-Heng Chen1,2,14, Shuo-Ming Ou1,2,8, Szu-Yuan Li1,2,8, Ming-Tsun Tsai1,2,8.   

Abstract

Patients with systemic lupus erythematosus (SLE) have a higher risk of vascular complications. This retrospective cohort study aimed to analyze the differences in the risk of arteriovenous fistula or graft (AVF/AVG) dysfunction in hemodialysis patients with and without SLE from Taiwan's National Health Insurance Database over a 10-year period. AVF/AVG dysfunction is defined as the occurrence of the first episode of intervention after vascular access creation. A total of 1366 HD patients with SLE had higher incidence rates of AVF/AVG dysfunction than 4098 non-SLE HD patients in the following 4 periods: (1) after 1 year (incidence rates = 15.21% and 13.01%, respectively; subdistribution hazard ratio (SHR) = 1.16; P = 0.007), (2) 1st-to-10th-year period (15.36% and 13.25%; SHR = 1.16; P = 0.007), (3) 5th-to-10th-year period (11.91% and 8.1%; SHR = 1.42; P = 0.003), and (4) overall period (23.53% and 21.66%; SHR = 1.09; P = 0.027). In conclusion, there were significantly higher incidence rates of AVF/AVG dysfunction in SLE patients during the long-term follow-up period. Vascular access function should be monitored regularly by clinical examinations, especially after 1 year and during 5 to 10 years, to improve AVF/AVG patency and dialysis adequacy in SLE patients undergoing maintenance hemodialysis.

Entities:  

Year:  2021        PMID: 34131224     DOI: 10.1038/s41598-021-92005-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

Review 1.  [Thrombosis and apoptosis].

Authors:  H Takeya; Y Tanaka; K Suzuki
Journal:  Rinsho Byori       Date:  1997-07

Review 2.  Activation of endothelial cells in thrombosis and vasculitis.

Authors:  P Cockwell; W Y Tse; C O Savage
Journal:  Scand J Rheumatol       Date:  1997       Impact factor: 3.641

Review 3.  Lupus protein-losing enteropathy (LUPLE): a systematic review.

Authors:  Sultan M Al-Mogairen
Journal:  Rheumatol Int       Date:  2011-02-23       Impact factor: 2.631

Review 4.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

Review 5.  Thrombosis and occlusion of vascular access in hemodialyzed patients.

Authors:  Martina Montagnana; Tiziana Meschi; Loris Borghi; Giuseppe Lippi
Journal:  Semin Thromb Hemost       Date:  2011-12-23       Impact factor: 4.180

6.  Risk of end-stage renal disease in systemic lupus erythematosus patients: a nationwide population-based study.

Authors:  Kuang-Hui Yu; Chang-Fu Kuo; I-Jun Chou; Meng-Jiun Chiou; Lai-Chu See
Journal:  Int J Rheum Dis       Date:  2016-02-10       Impact factor: 2.454

7.  Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus.

Authors:  O Vaarala; G Alfthan; M Jauhiainen; M Leirisalo-Repo; K Aho; T Palosuo
Journal:  Lancet       Date:  1993-04-10       Impact factor: 79.321

8.  Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis.

Authors:  S T Shafi; M Gupta
Journal:  J Vasc Access       Date:  2007 Apr-Jun       Impact factor: 2.283

Review 9.  Endothelial Alterations in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Potential Effect of Monocyte Interaction.

Authors:  Laura Atehortúa; Mauricio Rojas; Gloria M Vásquez; Diana Castaño
Journal:  Mediators Inflamm       Date:  2017-05-04       Impact factor: 4.711

10.  Prognosis of Vascular Access in Haemodialysis Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Tsung-Lun Lee; Chun-Fan Chen; Ann Charis Tan; Chia-Hao Chan; Shuo-Ming Ou; Fan-Yu Chen; Ko-Wen Yu; Yung-Tai Chen; Chih-Ching Lin
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.